Log in to save to my catalogue

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for...

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2640116805

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

About this item

Full title

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

Publisher

United States: Public Library of Science

Journal title

PloS one, 2022-01, Vol.17 (3), p.e0264138

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

FoundationOne
®
CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved companion diagnostic test to identify patients who may benefit from treatment in accordance with the approved therapeutic product labeling for 28 drug therapies. F1CDx utilizes next-generation sequencing (NGS)-based comprehensive genomic profiling...

Alternative Titles

Full title

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_2640116805

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2640116805

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0264138

How to access this item